前糖尿病および初期の 2 型糖尿病における個別化医療 (PREDICT)
Personalised Medicine in Prediabetes - Towards Preventing Diabetes in Individuals at Risk
Prediabetes is a common condition in overweight individuals affecting approximately 35% of American adults and 30% of Australian adults. Like diabetes, prediabetes is a serious risk factor for cardiovascular disease, eye, kidney and liver disease, and some types of cancer.
Appropriate blood glucose control is crucial in preventing pre-diabetes complications and onset of diabetes, yet clinical practice, backed by randomised trials, reports that many patients treated with standard dietary guidelines or with the first-line treatment of diabetes patients, metformin, do not improve blood glucose control sufficiently.
The overarching goal of the present project is to improve the efficacy of metformin mono-therapy in pre-diabetes and early type 2 diabetes.
調査の概要
詳細な説明
Prediabetes is common in overweight and obese individuals and, as with frank diabetes, it is a risk factor for cardiovascular disease, cognitive dysfunction, fatty liver, kidney, ophthalmic, renal and neuropathic disease, and cancer.
Effective management of dysglycemia in pre-diabetes and diabetes and prevention of diabetes in individuals at risk reduce the risk of organ damage and associated co-morbidities and improves the affected individuals' quality of life.
Metformin, an oral biguanide, is the first-line treatment of newly-diagnosed type 2 diabetes patients, and the pharmacological choice for preventing diabetes in individuals with pre-diabetes. Metformin is an ideal medication to initiate for diabetes prevention, due to its excellent safety profile (lack of hypoglycemia), neutral to marginally beneficial effect on body weight, evidence of cardio-protection, and low cost. However, clinical practice, backed by randomised clinical trials, suggests that metformin mono-therapy fails to achieve glycemic goals in 20-40% of type 2 diabetes patients and to prevent diabetes in approximately 20% of individuals with pre-diabetes.
While the mode of action of metformin is still being investigated, the liver and the gastrointestinal tract are thought to be the main targets responsible for the improvement in glycemia. An increasing body of evidence suggests that the gut microbiota play an important role in obesity, prediabetes and diabetes, and alterations in gut microbial composition have been described in individuals with type 2 diabetes and pre-diabetes. Interestingly, metformin-treated diabetes patients have a "healthier" gut microbial composition compared with treatment-naïve diabetes patients, and changes in gut microbial composition with metformin treatment has been suggested to contribute to the therapeutic effect of the medication.
Randomised, clinical study with parallel assignment and single-masking will be performed in treatment-naïve individuals with pre-diabetes or early type 2 diabetes (diagnosed in the last 6 months) aiming to compare the effect of metformin (extended release [XR]) 1500 mg/d administered with personalized diet (based on the Weizmann Institute Personalized Nutrition Project) or administered with a healthy (low fat) diet.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
New South Wales
-
Sydney、New South Wales、オーストラリア、2010
- Garvan Institute of Medical Research
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
- Prediabetes or early-stage type 2 diabetes according to the American Diabetes Association (2019) diagnostic criteria, with HbA1c ≤8.0% (64 mmol/mol).
- Women of childbearing potential willing to take precautions to avoid pregnancy throughout the study and for 3 months after the end of treatment.
- Willingness to provide written informed consent and willingness to participate and comply with the study.
Exclusion Criteria:
- Females planning a pregnancy during the course of the research or 3 months after completion of the research project. Females who breastfeed.
- Patients with type 1 diabetes, chronically active inflammatory disease, neoplastic disease in the previous 3 years, chronic gastrointestinal disorders, including inflammatory bowel disease or celiac.
- Liver enzymes ALT and/or AST>3-times normal range limit.
- Abnormal renal function as measured by (eGFR<45 mL/min/1.73m^2).
- Individuals with a history of a psychological illness or condition that may interfere with the individual's ability to understand the requirements of the study.
- Normo-glycaemia.
- HbA1c>8.0%
- Cardiovascular event in the previous 6 months.
- Current or recent (within 24 months) treatment with a glucose lowering medication (i.e. GLP-1 receptor agonist, SGLT2 inhibitor, thiazolidinedione, sulfonylurea, DPP-4 inhibitor or insulin).
- Current or recent (within 3 months) treatment with metformin.
- Treatment with an oral steroid.
- Treatment with antibiotics in the last 3 months.
- Treatment with immunosuppressive medications.
- Treatment with medications known to interact with metformin, including cimetidine, vitamin K antagonists and nifedipine.
- Substance abuse.
- Participants who had received an investigational new drug within the last 6 months.
- Participants involved in another clinical study.
- Participants who actively lose weight.
- Participants who had a bariatric surgery.
- Any reason the Investigator believes the participant is not likely to be adherent to the study treatment and protocol, including non-adherence to run-in.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Metformin + Healthy diet
Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet |
Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
他の名前:
|
|
アクティブコンパレータ:Metformin + Personalized diet
Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015) |
Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Mean change in glycated haemoglobin (HbA1C, %) from baseline
時間枠:6 months
|
Difference in the reduction of HbA1C between the groups |
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Total daily time of interstitial glucose levels below 7.8 mmol/L (140 mg/dL)
時間枠:6 months
|
Difference in the time (minutes) per day with interstitial glucose measured below 7.8 mmol/L (140 mg/dL) between the groups |
6 months
|
|
Glycaemic variability
時間枠:6 months
|
Difference in the glycaemic variability as derived from CGM between the groups |
6 months
|
|
Body weight
時間枠:6 months
|
Difference in the magnitude of weight loss between the groups |
6 months
|
|
Body fat mass
時間枠:6 months
|
Difference in body fat mass composition as assessed using dual-energy X-ray absorptiometry (DXA) between the groups |
6 months
|
|
Abdominal visceral fat volume
時間枠:6 months
|
Difference in the abdominal visceral fat volume as assessed using DXA between the groups |
6 months
|
|
Serum low-density lipoprotein (LDL)-cholesterol concentration
時間枠:6 months
|
Difference in serum LDL-cholesterol between the groups |
6 months
|
|
Serum high-density lipoprotein (HDL)-cholesterol concentration
時間枠:6 months
|
Difference in serum HDL-cholesterol concentration between the groups |
6 months
|
|
Serum triglycerides concentration
時間枠:6 months
|
Difference in serum triglycerides between the groups |
6 months
|
|
Blood pressure
時間枠:6 months
|
Difference in diastolic and systolic blood pressure between the groups |
6 months
|
|
Liver fat
時間枠:6 months
|
Difference in liver fat measured by the Fibroscan's controlled attenuation parameter (CAP) function between the groups |
6 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Gut microbiome (exploratory)
時間枠:6 months
|
Difference in gut microbiome features between the groups |
6 months
|
協力者と研究者
捜査官
- 主任研究者:Dorit Samocha-Bonet, PhD、Garvan Institute of Medical Research
- 主任研究者:Jerry Greenfield, MD, PhD、Garvan Institute of Medical Research
- 主任研究者:Eran Elinav, MD, PhD、Weizmann Institute of Science
- 主任研究者:Eran Segal, PhD、Weizmann Institute of Science
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- SVH 17/080
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。